How Long Can You Stay on Zepbound for Effective Weight Management?

Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no time limit in the Zepbound labeling — the FDA-approved indication is explicitly long term. The Zepbound prescribing information states the medication is indicated "to reduce excess body weight and maintain weight reduction long term" in adults with obesity, or with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It is also indicated for moderate-to-severe obstructive sleep apnea in adults with obesity. Nothing in that labeling caps treatment at six months, a year, or any other interval. How long you stay on it is a clinical judgment your prescriber makes with you, revisited over time — not a countdown built into the drug.

The Label Does Not Set an End Date

People often expect weight medications to work like a course of antibiotics: finish the bottle, the problem is resolved, you stop. The phrase "maintain weight reduction long term" in the Zepbound indication signals something different. Maintenance is written into the approved purpose of the drug, which means the FDA reviewed evidence not only that people lose weight on it but that continuing it is how the reduction is held.

The clinical program behind the approval reflects that. Efficacy was assessed across 72 weeks of continuous treatment in the pivotal obesity trial, with maintenance dosing continued throughout rather than tapered off at a fixed point. Labeled maintenance dosages are 5 mg, 10 mg, or 15 mg once weekly for weight reduction, and 10 mg or 15 mg once weekly for obstructive sleep apnea. Which of those applies to any individual, and for how long, is a prescriber decision informed by response and tolerability.

What Happened When People Stopped: SURMOUNT-4

The most direct evidence on duration comes from a randomized withdrawal trial. In SURMOUNT-4, published in JAMA, 783 adults with obesity or overweight and a weight-related complication — diabetes excluded — entered a 36-week open-label lead-in on the maximum tolerated dose. At week 36 the 670 who completed it were randomized 1:1 either to continue the medication or to switch to placebo for another 52 weeks.

The lead-in produced a mean weight reduction of 20.9%. Over the following 52 weeks, the group that continued lost a further 5.5% on average, while the group switched to placebo regained 14.0% — a between-group difference of 19.4 percentage points. At week 88, 89.5% of those who continued had held on to at least 80% of the weight they had lost during the lead-in, compared with 16.6% of those who had stopped. Across the full 88 weeks, mean reduction was 25.3% with continued treatment versus 9.9% with placebo.

A 2026 Trial Tested Staying On, Stepping Down, or Stopping

SURMOUNT-4 answered the binary question. A larger design published in The Lancet in 2026 asked a more useful one: is there a middle path between full-dose continuation and stopping altogether? The SURMOUNT-MAINTAIN trial ran 112 weeks across 20 US sites — a 60-week open-label weight-loss period followed by a 52-week double-blind maintenance period. At week 60, 378 participants were randomized 3:3:2 to continue at their maximum tolerated dose, reduce to 5 mg, or switch to placebo.

At week 112, mean change in body weight from baseline was −21.9% for those who continued at maximum tolerated dose, −16.6% for those reduced to 5 mg, and −9.9% for those switched to placebo. The proportion of participants who needed rescue treatment because they had regained more than half of what they lost tells the same story from another angle: 8% in the continuation group, 25% in the dose-reduction group, and 67% in the placebo group. The investigators concluded that continuing treatment maintained the reduction, and that stepping down "might provide a valuable alternative to discontinuation, although individuals' treatment response might vary."

Why the Weight Comes Back

Regain after stopping is not a failure of willpower and it is not unique to this class of medication. Obesity behaves as a chronic, relapsing condition with active physiological defense of a higher body weight. Appetite-regulating signaling, gastric emptying, and energy expenditure all shift after weight loss in directions that favor regain, and those shifts persist long after the weight is gone.

A medication that acts on incretin signaling suppresses that defense while it is present in the body. Remove it, and the underlying biology is still there. That is why the withdrawal data look the way they do, and it is the central reason the labeled indication is framed around long-term maintenance rather than a defined treatment course.

What Actually Ends Treatment for Most People

In practice, the limiting factors are rarely regulatory. Tolerability is one: gastrointestinal adverse reactions were the most common in every trial in the program, mostly mild to moderate and concentrated during dose escalation, but not universally manageable. Coverage and cost are the others, and they are often decisive, since plans may cover a weight-management indication for a limited period or not at all.

Continuity of supply matters as much as efficacy, because a medication that has to be interrupted for months does not deliver what the maintenance data describe. If affordability is what would end your treatment, that is a conversation to have with your prescriber before you stop, not after.

Two Indications, Two Reasons to Continue

Zepbound carries a second approved indication that changes the duration question for some people. It is approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity. For someone treating both conditions, the medication is doing two jobs, and the calculus around continuing is not only about the number on the scale.

The labeling also notes that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. That matters if a duration conversation turns into a switching conversation — the two products should not be stacked, and any transition belongs to the prescriber.

How the Duration Decision Gets Made

A reasonable review looks at whether the reduction achieved is being maintained, whether weight-related conditions have improved, whether adverse reactions are tolerable, and whether the treatment remains obtainable and affordable. Those four inputs change over time, which is why duration is reassessed rather than decided once.

What no article can tell you is which of those inputs applies to you, or what your prescriber should do about it. Bring the question to the clinician who wrote your prescription, and use the pharmacy label as the authority on anything practical about the product you were dispensed.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is there a maximum time you can stay on Zepbound?

No maximum duration appears in the FDA labeling. The approved indication is to reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity. Duration is a clinical judgment your prescriber revisits over time based on response, tolerability, and your overall health picture.

What did trials show when people stopped taking it?

In the SURMOUNT-4 randomized withdrawal trial, participants lost a mean of 20.9% during a 36-week open-label lead-in. Over the next 52 weeks, those who continued lost a further 5.5% on average while those switched to placebo regained 14.0%. At week 88, 89.5% of the continuation group had maintained at least 80% of their lead-in weight loss, versus 16.6% of those who stopped.

Can the dose be lowered instead of stopping entirely?

The SURMOUNT-MAINTAIN trial tested exactly that over 112 weeks. Participants reduced to 5 mg were at −16.6% from baseline at week 112, between those who continued at maximum tolerated dose (−21.9%) and those switched to placebo (−9.9%). The investigators described dose reduction as a possible alternative to stopping, while noting individual response varies. Only your prescriber can decide whether it applies to you.

Why does weight return after stopping?

Obesity behaves as a chronic, relapsing condition. After weight loss, appetite signaling, gastric emptying, and energy expenditure shift in directions that defend a higher body weight, and those changes persist. Incretin-based medication suppresses that defense while it is present in the body; when it is withdrawn, the underlying biology remains. That is why the labeled indication is framed around long-term maintenance rather than a fixed course.

Is Zepbound the same as Mounjaro?

Both contain tirzepatide, but they are separate FDA applications with separate labeling. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. Neither should be combined with the other.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.